%0 Journal Article %A Riyad N.H. Seervai %A Rahul K. Jangid %A Menuka Karki %A Durga Nand Tripathi %A Sung Yun Jung %A Sarah E. Kearns %A Kristen J. Verhey %A Michael A. Cianfrocco %A Bryan A. Millis %A Matthew J. Tyska %A Frank M. Mason %A W. Kimryn Rathmell %A In Young Park %A Ruhee Dere %A Cheryl L. Walker %T SETD2 is an actin lysine methyltransferase %D 2020 %R 10.1101/2020.04.13.034629 %J bioRxiv %P 2020.04.13.034629 %X SET-domain-containing-2 (SETD2) was identified as the methyltransferase responsible for the histone 3 lysine 36 trimethyl (H3K36me3) mark of the histone code. Most recently, SETD2 has been shown to be a dual-function remodeler that regulates genome stability via methylation of dynamic microtubules during mitosis and cytokinesis. Here we show that actin is a bona fide target for methylation by SETD2 in vitro and in cells. Antibodies against the SETD2 trimethyl lysine epitope recognize methylated actin, with this methyl mark localizing to areas of active actin cytoskeleton reorganization in migrating cells. Disruption of this methylation activity causes defects in actin polymerization and impairs collective cell migration. Together, these data identify SETD2 as a multifunctional cytoskeletal remodeler regulating methylation and polymerization of actin filaments, and provide new avenues for understanding how defects in SETD2 drive disease via aberrant cytoskeletal methylation.Competing Interest StatementThe authors have declared no competing interest. %U https://www.biorxiv.org/content/biorxiv/early/2020/04/14/2020.04.13.034629.full.pdf